Patients with ACS who received prasugrel before PCI, showed less endothelial dysfunction and platelet aggregation, while those on clopidogrel and ticagrelor did not, nor did treatment after PCI.

Erin Bohula explains which determinants of residual CV risk we nowadays know and presents study results on how to target these.

AHA 2019 The COLCHICINE-PCI trial investigated whether a single dose of the anti-inflammatory agent colchicine, given prior to PCI, resulted in reduced vascular inflammation and myocardial injury after PCI.

AHA 2019 Pradhan was the discussant of the COLCOT trial. She put the results in the broader perspective of managing inflammation as a means to lower CV risk.

AHA 2019 Dr. Tardif summarizes the study design and results of the COLCOT trial, in which colchicine treatment was found to lower a composite endpoint in patients soon after MI.

AHA 2019 Daily colchicine lowered ischemic events, mostly urgent revascularization, in patients with an MI less than 30 days ago, in the COLCOT trial. Colchicine was well-tolerated.

CSI Paris Steven Hageman asks Cilie van 't Klooster about her study on the relationship between CRP levels and risk of incident cancer and recurrent CV events in subjects with stable CVD in the SMART-cohort.

Data of the BIOSTAT-CHF cohort suggest that the etiology of ID in worsening HF is multifactorial and may involve a combination of reduced iron uptake, impaired iron storage and iron loss.

Prof. Ray describes the high residual CV risk in post-ACS diabetes patients, and how BET inhibition with apabetalone may reduce this residual risk and thereby prevent CV events.

Prof. Libby discusses the inflammatory residual risk in diabetes patients and explains how epigenetic modulation of (inflammatory) gene transcription can potentially reduce CV risk.

A biomarker analysis in a subgroup of CANTOS participants shows that plasma levels of cytokines IL-6 and IL-18 are related to future CV risk both before and after treatment with canakinumab.

Data of a prospective cohort suggest that chronic systemic low-grade inflammation, as measured by CRP, plays a role in development of cancer, particularly of the lung, in those with stable CVD.